June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Success of Micropulse Cyclophotocoagulation following Tube Shunt Surgery
Author Affiliations & Notes
  • Michael Edmund Offutt
    Ophthalmology, The University of Texas Health Science Center at San Antonio Joe R and Teresa Lozano Long School of Medicine, San Antonio, Texas, United States
  • Braedon Moody
    Ophthalmology, The University of Texas Health Science Center at San Antonio Joe R and Teresa Lozano Long School of Medicine, San Antonio, Texas, United States
  • Ahmad Kheirkhah
    Ophthalmology, The University of Texas Health Science Center at San Antonio Joe R and Teresa Lozano Long School of Medicine, San Antonio, Texas, United States
  • Corey Waldman
    Ophthalmology, The University of Texas Health Science Center at San Antonio Joe R and Teresa Lozano Long School of Medicine, San Antonio, Texas, United States
  • Footnotes
    Commercial Relationships   Michael Offutt, None; Braedon Moody, None; Ahmad Kheirkhah, None; Corey Waldman, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2562. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Edmund Offutt, Braedon Moody, Ahmad Kheirkhah, Corey Waldman; Success of Micropulse Cyclophotocoagulation following Tube Shunt Surgery. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2562.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the outcomes of micropulse cyclophotocoagulation (MP-CPC) in patients with and without a history of tube shunt surgery.

Methods : This is a retrospective chart review of patients who underwent MP-CPC from May 2017 to December 2020, comparing those with and without a history of tube shunt surgery. The treatment group is referred to as the tube-group and the control group is referred to as the non-tube group. All forms of glaucoma were included, and the patients were followed for at least 12 months. Success (S) was defined by an intraocular pressure (IOP) of 8-18mmHg, requiring fewer drops than before MP-CPC, vision greater than no light perception (NLP), and requiring no further intervention. If any alternative procedural (i.e. repeat MP-CPC) or surgical intervention was required to control IOP, this would qualify as a failure.

Results : The tube group (n=21) had an average age of 57.62 ± 10.53, male preponderance (52.4%), and neovascular glaucoma the most common glaucoma diagnosis. 57.1% of the tube group was phakic. This contrasts to the non-tube group (n=41) with average age of 59.68 ± 15.7, female preponderance (53.7%), and primary open angle glaucoma the most common diagnosis (46.3%). Pre-op IOP for the tube group was 28.29 ± 7.68 with the number of pre-op topical glaucoma medications 3.90 ± 0.525; pre-op IOP for the non-tube group was 30.46 ± 10.68 with the number of topical glaucoma medications 3.29 ± 0.74 (P=0.37). Principal data suggests greater success in the tube group than the non-tube group at six months of follow up (IOP of 14.6 versus 15.67; P=0.024). In addition, at 3-, 6-, and 12- month follow ups, there were statistically significant decreases in IOP and the number of medications used for the tube group – 13.5mmHg with 2.67 topical drops, 14.6mmHg with 2.67 topical drops, and 12.33mmHg with 2.50 topical drops. For the 3-, 6-, and 12- month follow ups, the success rate, as defined above, was 33% & 17%, 43% & 14%, and 33% & 7% for the tube group and the non-tube group, respectively. The most common complication was hypotony (as defined by ≤7mmHg) occurring four times in each group.

Conclusions : This data suggests that MP-CPC is more effective in patients with previous tube shunt surgery compared to those without while maintaining a good safety profile.

This is a 2021 ARVO Annual Meeting abstract.

 

IOP and topical glaucoma medications (# drops) with and without previous tube shunt surgery; post-operative day (POD), fail (F), missing (M)

IOP and topical glaucoma medications (# drops) with and without previous tube shunt surgery; post-operative day (POD), fail (F), missing (M)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×